Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

StemiRNA Therapeutics Appoints Dr. Jack Hu As Chief Financial Officer

StemiRNA, a leader in research and development of mRNA therapeutics, welcomes Dr. Jack Hu as Chief Financial Officer. Dr. Hu brings nearly two decades of experience in healthcare investment research, financial management and corporate strategy. Dr. Hu started his career in US Pharmaceutical industry and then moved on to Wall Street to cover US biotechnology stocks at Sellside banks, later he also ran book at buyside. Subsequently, Dr. Hu served as the Managing Director and Head of APAC Healthcare Research at Deutsche Bank, where he covered Asia/China healthcare. He was ranked No.1 for All-China healthcare research by Institutional Investor Magazine from 2015 to 2017 at StemiRNA, Dr. Hu will oversee finance management and investor relations while providing support to the company’s overall strategy planning and corporate development. 

PREDICTIONS-SERIES-2022

Recommended AI News: Trust Payments Announces its New Crypto Partnership with Everest

“We are thrilled to have Jack join the team and bring his industry expertise and insights to our fast-growing platform”, said Dr. Hangwen Li, Chairman and CEO of StemiRNA Therapeutics, “Jack excels in strategic planning and execution of portfolio management, on top of a proven track record in the capital market and investment community. We are excited to work as a team to build corporate partnerships and our strategic financial capabilities. As CFO, his leadership, expertise and network are instrumental to assist us in building a global mRNA therapeutic company.”

Related Posts
1 of 33,197

Recommended AI News: Geojam’s $JAM Token Lifts Off from Lattice Launchpad after $5.9 Million Private Sale

“I am humbled and excited to join Hangwen and the talented leadership team, as StemiRNA emerges as a disruptive mRNA platform company with a broad pipeline.” Commented Dr. Jack Hu, “I look forward to working with this dedicated team to create value for shareholders.”

Recommended AI News: YipitData Raises up to $475 million in Series E Funding from Carlyle

[To share your insights with us, please write to sghosh@martechseries.com]

Comments are closed.